Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.66 USD -3.54% Intraday chart for Citius Pharmaceuticals, Inc. +1.79% -12.76%
May. 21 Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution CI
May. 14 Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI

Evolution of the average Target Price on Citius Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

52e.IrpBhfDRAzQySsvhS1Ku0GTyZFjONWDw8BOYWqONW80.c9wOycCIcVcDHpqFI2Pqn12fIy6ZBjnHxFLXCsb9GKpU8DjoiKJJYUEyqA~da877730731e2f636ed8064b582c697c

Analyst Recommendations on Citius Pharmaceuticals, Inc.

HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $4 From $6, Maintains Buy Rating MT
HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $6 From $4, Maintains Buy Rating MT
Maxim Group Initiates Coverage on Citius Pharmaceuticals With Buy Rating, $4 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.66 USD
Average target price
4 USD
Spread / Average Target
+506.06%
High Price Target
4 USD
Spread / Highest target
+506.06%
Low Price Target
4 USD
Spread / Lowest Target
+506.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Citius Pharmaceuticals, Inc.

HC Wainwright
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. Consensus Citius Pharmaceuticals, Inc.